
Johnson & Johnson (JNJ) Stock
Global healthcare giant with medicines, devices and consumer goods. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in November 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving

J&J Pipeline Momentum Outweighs Legal Headwinds as Analysts Eye Downside
- Clinical pipeline advances: J&J announced positive Phase 3 data for CAPLYTA in bipolar mania and ICOTYDE in psoriatic arthritis, alongside promising Phase 1 results for an investigational prostate cancer immunotherapy combination showing a 73% PSA response rate.
- Legal and regulatory pressure: A Massachusetts jury awarded $3.3 million to a family in a mesothelioma case linked to talcum-based baby powder, while Pomerantz Law Firm launched an investigation into claims on behalf of investors.
- Market sentiment divergence: Despite a 10.4% rise since the last earnings report and strong oncology sales surging 16.8% year-to-date, some analysts highlight a -13% downside risk, contrasting with views that position J&J as a stable 'anti-AI' play amid broader tech sell-offs.

J&J Pipeline Momentum Outweighs Legal Headwinds as Analysts Eye Downside
- Clinical pipeline advances: J&J announced positive Phase 3 data for CAPLYTA in bipolar mania and ICOTYDE in psoriatic arthritis, alongside promising Phase 1 results for an investigational prostate cancer immunotherapy combination showing a 73% PSA response rate.
- Legal and regulatory pressure: A Massachusetts jury awarded $3.3 million to a family in a mesothelioma case linked to talcum-based baby powder, while Pomerantz Law Firm launched an investigation into claims on behalf of investors.
- Market sentiment divergence: Despite a 10.4% rise since the last earnings report and strong oncology sales surging 16.8% year-to-date, some analysts highlight a -13% downside risk, contrasting with views that position J&J as a stable 'anti-AI' play amid broader tech sell-offs.
Sixth Month Growth Performance
When is the next earnings date for Johnson & Johnson (JNJ)?
No confirmed upcoming earnings date has been announced for Johnson & Johnson as of the current reporting period. Based on the company's historical pattern of quarterly releases, the next report is expected in January 2026. This anticipated release will cover financial results for the fourth quarter and full year of fiscal 2025. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Johnson & Johnson's stock with a target price of $227.43, indicating potential growth.
Financial Health
Johnson & Johnson is performing well with solid revenue and cash flow, indicating financial stability.
Dividend
Johnson & Johnson's dividend yield of 1.84% offers a modest return for those seeking dividend income. If you invested $1000 you would be paid $18.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.